A comprehensive survival analysis using the TCGA database revealed that glioma patients with elevated STAT3 expression had reduced overall survival, progress free interval, and disease specific survival compared to those with expressed lower levels of STAT3 (p < 0.001, Figures 3B–D). This evidence concerns the gene STAT3 and glioma.